OptimizeRx Q2 revenue beats estimates on operating resilience; reaffirms outlook
OptimizeRx Q2 revenue beats estimates on operating resilience; reaffirms outlook
Overview
US healthcare tech firm's Q2 revenue fell 30% yr/yr but beat analyst expectations
Q2 adjusted EBITDA and non-GAAP EPS beat analyst expectations
Company reaffirmed 2026 revenue and adjusted EBITDA guidance
Outlook
Company reaffirms 2026 revenue guidance of $95 mln to $100 mln
Company maintains 2026 adjusted EBITDA forecast of $21 mln to $25 mln
Company cites variability in second-half timing and mix but sees commercial momentum supporting outlook
Result Drivers
CUSTOMER CONCENTRATION - Co said revenue decline was concentrated among a small number of customers, while other customers increased investment
PRODUCT INNOVATION - Recent product launches and expanded programmatic initiatives strengthened customer engagement, according to CEO Stephen L. Silvestro
MARGIN EXPANSION - Co said Q2 revenue and adjusted EBITDA exceeded consensus, reflecting margin expansion and disciplined execution
Company press release: ID:nGNX6KqRnF
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $20.50 mln | $20.20 mln (6 Analysts) |
Q2 Adjusted EPS | Beat | $0.16 | $0.12 (4 Analysts) |
Q2 Adjusted Net Income | Beat | $3.10 mln | $1.95 mln (4 Analysts) |
Q2 Adjusted EBITDA | Beat | $4.90 mln | $2.39 mln (6 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the online services peer group is "buy"
Wall Street's median 12-month price target for OptimizeRx Corporation is $11.00, about 59% above its August 11 closing price of $6.92
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 6 three months ago
Reuters Recommended Reads
Aug 10 - Definitive Healthcare Q2 revenue slightly misses estimates despite customer gains
Aug 10 - Viant Technology Q2 revenue beats estimates on attention intelligence integration
Aug 11 - Inuvo Q2 revenue misses on Legacy Search decline
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on OptimizeRx
See all newsBrief: Optimizerx Announces Finance Leadership Appointments To Support The Next Phase Of Growth
OptimizeRx Corporation reports results for the quarter ended June 30 - Earnings Summary
OptimizeRx Q2 revenue beats estimates on operating resilience; reaffirms outlook
OptimizeRx Corporation expected to post earnings of 12 cents a share - Earnings Preview
Brief: Optimizerx Corp - Enters Credit Agreement With Fifth Third Bank On May 7, 2026 - SEC Filing